DE3584260D1 - Die synthese eines proteins mittels eines identifizierungspeptids. - Google Patents

Die synthese eines proteins mittels eines identifizierungspeptids.

Info

Publication number
DE3584260D1
DE3584260D1 DE8585300432T DE3584260T DE3584260D1 DE 3584260 D1 DE3584260 D1 DE 3584260D1 DE 8585300432 T DE8585300432 T DE 8585300432T DE 3584260 T DE3584260 T DE 3584260T DE 3584260 D1 DE3584260 D1 DE 3584260D1
Authority
DE
Germany
Prior art keywords
identification peptide
functional protein
protein
hybrid polypeptide
terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585300432T
Other languages
English (en)
Inventor
Thomas P Hopp
Susan L Bektesh
Iii Paul J Conlon
Carl J March
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Aldrich Co LLC
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24293537&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3584260(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DE3584260D1 publication Critical patent/DE3584260D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/28—Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE8585300432T 1984-01-24 1985-01-23 Die synthese eines proteins mittels eines identifizierungspeptids. Expired - Lifetime DE3584260D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/573,825 US4703004A (en) 1984-01-24 1984-01-24 Synthesis of protein with an identification peptide

Publications (1)

Publication Number Publication Date
DE3584260D1 true DE3584260D1 (de) 1991-11-07

Family

ID=24293537

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585300432T Expired - Lifetime DE3584260D1 (de) 1984-01-24 1985-01-23 Die synthese eines proteins mittels eines identifizierungspeptids.

Country Status (5)

Country Link
US (1) US4703004A (de)
EP (1) EP0150126B1 (de)
JP (1) JPH074255B2 (de)
AT (1) ATE68014T1 (de)
DE (1) DE3584260D1 (de)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162898A4 (de) * 1983-11-14 1987-07-23 Chiron Corp Interleukin-2-erzeugung unter verwendung klonierter gene für interleukin-2 und hefe alpha-faktor.
US5691181A (en) * 1984-08-21 1997-11-25 Celltech Limited DNA encoding lipase from human gastric mucosal tissue
US6808901B1 (en) * 1984-09-03 2004-10-26 Celltech R&D Limited Production of chimeric antibodies
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5853978A (en) * 1985-12-04 1998-12-29 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and methods of use
US6534285B1 (en) * 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
JPS61264000A (ja) * 1985-03-21 1986-11-21 イミユネツクス　コ−ポレイシヨン 標識ペプチドによるタンパク質の合成
EP0207044A1 (de) * 1985-06-20 1986-12-30 Monsanto Company Freisetzung von Peptiden aus Polypeptiden
EP0440311A1 (de) * 1985-06-20 1991-08-07 Fujisawa Pharmaceutical Co., Ltd. Herstellungsverfahren für menschliches alpha-Atrio-natriuretisches Polypeptid
US4828799A (en) * 1985-06-26 1989-05-09 Research Corporation Therapeutic drug monitoring and analyte determination utilizing micellar chromatography
FR2594846B1 (fr) * 1986-02-21 1989-10-20 Genetica Procede de preparation de la serum albumine humaine mature
SE8601940D0 (sv) * 1986-04-25 1986-04-25 Kabigen Ab Preparation of fused proteins, antibodies and processes therefor
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5215896A (en) * 1987-03-20 1993-06-01 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
US5200509A (en) * 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
FR2615528B1 (fr) * 1987-05-18 1991-05-24 Pasteur Institut Procede de production d'un polypeptide ayant des proprietes choisies determinees, dans un organisme-hote transforme par un adn recombinant contenant des sequences nucleiques codant pour ce polypeptide et pour une proteine affine d'ose
ZA887773B (en) 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
PT89121A (pt) * 1987-12-04 1989-12-29 Du Pont Processo para a preparacao de interleuquina-2 imobilizada e interleuquina-2 contendo uma extensao no terminal-carboxilo com actividade de interleuquina-2 natural
US4931498A (en) * 1988-02-25 1990-06-05 Purdue Research Foundation Immobilized artificial membranes
US4927879A (en) * 1988-02-25 1990-05-22 Purdue Research Foundation Method for solid phase membrane mimetics
USRE39760E1 (en) * 1988-03-31 2007-08-07 International Bio-Immune Systems Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
US5108919A (en) * 1988-06-24 1992-04-28 Genentech, Inc. Dna sequences encoding yeast ubiquitin hydrolase
US5262322A (en) * 1988-06-24 1993-11-16 Genentech, Inc. Host transformed with yeast gene and ubiquitin/polypeptide fusions
US5156968A (en) * 1988-06-24 1992-10-20 Genentech, Inc. Purified yeast ubiquitin hydrolase
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
ATE123065T1 (de) * 1989-07-07 1995-06-15 Takeda Chemical Industries Ltd Proteine und deren herstellung.
US7413537B2 (en) * 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
WO1992017583A1 (en) 1991-03-29 1992-10-15 Immunex Corporation Isolated viral protein cytokine antagonists
US5595887A (en) * 1990-07-16 1997-01-21 Bionebraska, Inc. Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment
AU8740491A (en) * 1990-09-28 1992-04-28 Protein Engineering Corporation Proteinaceous anti-dental plaque agents
JPH07108232B2 (ja) * 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 ペプチド又は蛋白質の製造方法
US6083686A (en) * 1990-10-26 2000-07-04 Johnson & Johnson Clinical Diagnostic Systems, Inc. Increased production of Thermus aquaticus DNA polymerase in E. coli
SK60893A3 (en) * 1990-12-13 1993-10-06 Upjohn Co Fusion polypeptides
US5270197A (en) * 1990-12-20 1993-12-14 The Children's Medical Center Corporation Cells expressing a substantial number of surface high affinity HBGF receptors but relatively few low affinity HBGF binding sites and system for assaying binding to HBGF receptor
AU1545692A (en) * 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
US5712381A (en) * 1994-10-19 1998-01-27 Genetics Institute, Inc. MADD, a TNF receptor death domain ligand protein
US5852173A (en) * 1994-10-19 1998-12-22 Genetics Institute, Inc. TNF receptor death ligand proteins and inhibitors of ligand binding
US5731425A (en) * 1994-10-28 1998-03-24 Eastman Kodak Company Polypeptide surface marker for cells
AU4415796A (en) * 1994-12-07 1996-06-26 Bionebraska, Inc. Production of c-terminal amidated peptides from recombinant protein constructs
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
KR100510234B1 (ko) 1995-06-29 2005-11-25 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
US6037149A (en) 1995-08-24 2000-03-14 Magainin Pharmaceuticals Inc. DNA encoding human asthma associated factor 1
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US20040219149A1 (en) 2001-06-08 2004-11-04 Yuhong Zhou Methods for the modulation of il-13
CA2376717A1 (en) * 1999-06-16 2000-12-21 Icos Corporation Human poly(adp-ribose) polymerase 2 materials and methods
US6379903B1 (en) 1999-10-08 2002-04-30 Sigma-Aldrich Co. Purification of recombinant proteins fused to multiple epitopes
AU2001281464A1 (en) * 2000-03-13 2001-09-24 Monsanto Technology Llc Recombinant proteins containing repeating units
EP1939203B1 (de) 2000-04-25 2014-11-19 ICOS Corporation Hemmer der delta-Isoform der menschlichen Phosphatidyl-Inositol-3-Kinase
ATE502941T1 (de) 2000-04-25 2011-04-15 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta
IL155307A0 (en) * 2000-10-10 2003-11-23 Univ Oklahoma Methods for isolating, identifying and purifying peptide ligands and peptide ligands produced thereby
US6756215B1 (en) 2000-10-20 2004-06-29 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Functionalized TGF-β fusion proteins
WO2004022006A2 (en) 2002-09-09 2004-03-18 Arbor Vita Corporation Methods of diagnosing cervical cancer
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
EP1385866A4 (de) * 2001-04-05 2006-03-29 Univ Nebraska Alkoholoxidase-1 regulierende nukleotidsequenzen für die heterologe genexpression in hefe
US7101977B2 (en) 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US8088602B1 (en) 2001-12-05 2012-01-03 Elizabeth Gay Frayne Manipulation of RNA stability and protein synthesis using thio-phosphate
EP1481073B1 (de) 2002-03-01 2009-11-11 Monsanto Technology LLC Wachsestersynthase-dna-sequenz, protein und verwendungen davon
US7799561B2 (en) * 2002-06-12 2010-09-21 Sigma-Aldrich, Co. Affinity peptides and method for purification of recombinant proteins
WO2004025259A2 (en) * 2002-09-12 2004-03-25 Molecular Probes, Inc. Site-specific labeling of affinity tags in fusion proteins
BRPI0406662A (pt) * 2003-01-09 2005-12-20 Macrogenics Inc Vetor, célula, método de identificar um mab, e, composição
JP2006525807A (ja) * 2003-05-02 2006-11-16 シグマ−アルドリッチ・カンパニー 固相細胞溶解および捕捉プラットフォーム
EP1648935A2 (de) 2003-07-25 2006-04-26 Amgen Inc. Antagonisten und agonisten von ldcam und anwendungsverfahren
US20050178959A1 (en) * 2004-02-18 2005-08-18 Viorica Lopez-Avila Methods and compositions for assessing a sample by maldi mass spectrometry
US7932260B2 (en) 2004-05-13 2011-04-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2006026248A1 (en) 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US7741053B2 (en) * 2005-05-13 2010-06-22 Sigma-Aldrich Co. Processes for purification of recombinant proteins
JP2008546392A (ja) * 2005-06-17 2008-12-25 バイオレクシス ファーマシューティカル コーポレーション 固定されたトランスフェリン融合タンパク質ライブラリー
US20070275416A1 (en) * 2006-05-16 2007-11-29 Gsf-Forschungszentrum Fuer Umwelt Und Gesundheit Gmbh Affinity marker for purification of proteins
EP1878744A1 (de) * 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-Tag für an der Oberfläche exprimierte T-Zell Rezeptor Proteine, deren Anwendung und Verfahren zur Selection von Wirtszellen, die sie exprimieren
EP2061887B1 (de) * 2006-10-04 2018-01-24 The University Of Queensland Zuführungssystem für impfstoff gegen grippe auf vlp-basis
EP2083073B1 (de) 2006-10-11 2013-09-04 Oriental Yeast Co., Ltd. Fusionsprotein aus löslichem rankl mit epitop-tag enthaltendes reagens
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
MX2009006398A (es) 2006-12-12 2009-06-23 Biorexis Pharmaceutical Corp Genotecas de proteinas de fusion de transferrina.
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2680832A1 (en) * 2007-03-27 2008-10-02 Merck & Co., Inc. Method for detecting autoprocessed, secreted pcsk9
US7897369B2 (en) * 2007-08-27 2011-03-01 Regents Of The University Of Minnesota Isoprenoid wax ester synthases, isoprenoid acyl CoA-synthetases, and uses thereof
WO2009064802A2 (en) * 2007-11-13 2009-05-22 Eli Lilly & Co. Inhibitors of human phosphatidyl-inositol 3-kinase delta
EP2229446A4 (de) 2007-12-05 2011-06-22 Univ Georgia Hydrogenase-polypeptid und verwendungsverfahren
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
EP2265730B1 (de) 2008-03-12 2018-06-06 The Rockefeller University Verfahren und vorrichtungen zur erstellung von translationsprofilen und molekularen phänotypisierung
CN102137675A (zh) 2008-04-17 2011-07-27 Pds生物科技公司 通过阳离子脂质的对映体刺激免疫应答
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US20120094347A1 (en) 2008-09-18 2012-04-19 University Of Georgia Research Foundation, Inc. Methods and compositions for degrading pectin
WO2010054108A2 (en) * 2008-11-06 2010-05-14 University Of Georgia Research Foundation, Inc. Cas6 polypeptides and methods of use
WO2010058023A1 (en) 2008-11-24 2010-05-27 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh High affinity t cell receptor and use thereof
WO2010089412A1 (en) 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
EP2258719A1 (de) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Mehrfachziel-T-Zellen-Rezeptor
PT2456786E (pt) 2009-07-24 2014-03-25 Immune Design Corp Vetores lentivirais pseudotipados com uma glicoproteína do envelope do vírus sindbis
GEP20166504B (en) 2009-10-23 2016-06-27 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
WO2011056954A2 (en) 2009-11-04 2011-05-12 Regents Of The University Of Minnesota Haemophilus parasuis polypeptides and methods of use
WO2011066460A1 (en) * 2009-11-27 2011-06-03 Msdx, Inc. Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition
US8440651B2 (en) 2010-02-22 2013-05-14 F. Hoffmann-La Roche Ag Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use
US20110301568A1 (en) 2010-06-04 2011-12-08 Medtronic, Inc. Systems and Methods to Treat Cardiac Pacing Conditions
RU2013104038A (ru) 2010-07-14 2014-08-20 Ф. Хоффманн-Ля Рош Аг СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ PI3K p110 ДЕЛЬТА ПУРИНОВЫЕ СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
US20130224191A1 (en) 2010-08-27 2013-08-29 Robert A. Stull Notum protein modulators and methods of use
CA2809864A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
BR112013005116A2 (pt) 2010-09-03 2019-09-24 Stem Centrx Inc moduladores e métodos de uso
PE20171143A1 (es) 2010-12-08 2017-08-10 Stem Centrx Inc Nuevos moduladores y metodos para su uso
US9339526B2 (en) 2011-01-17 2016-05-17 University Of Manitoba Methods for treating disorders that involve immunoglobulin A
US8673309B2 (en) * 2011-02-11 2014-03-18 Msdx, Inc. Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1
AU2012217723A1 (en) 2011-02-15 2013-08-29 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
WO2012154272A1 (en) 2011-02-25 2012-11-15 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
DK2822967T3 (da) 2012-03-09 2019-10-07 Csl Behring Ag Compositions comprising secretory - like immunoglobulins
US9611306B2 (en) 2012-03-28 2017-04-04 The Board Of Regents Of The University Of Texas System TGFB type II-type III receptor fusions
KR102070472B1 (ko) 2012-03-30 2020-01-29 이뮨 디자인 코포레이션 Dc-사인을 발현하는 세포에 대해 개선된 형질도입 효능을 갖는 렌티바이러스 벡터 입자
WO2014039879A1 (en) 2012-09-06 2014-03-13 North Carolina State University Sequestration of carbon dioxide with hydrogen to useful products
US20150250872A1 (en) 2012-09-21 2015-09-10 Frank Bedu-Addo Vaccine compositions and methods of use
US10036047B2 (en) 2013-06-10 2018-07-31 University Of Georgia Research Foundation, Inc. Methods for hydroxylating phenylpropanoids
US9353390B2 (en) 2013-06-13 2016-05-31 University Of Georgia Research Foundation, Inc. Genetically engineered microbes and methods for producing 4-hydroxycoumarin
EP3030249B1 (de) 2013-08-07 2019-12-25 Rigshospitalet, Copenhagen University Hospital Antikörper, verbindungen und derivate davon zur verwendung in der behandlung männlicher unfruchtbarkeit
EP3038634A4 (de) 2013-08-28 2017-10-11 AbbVie Stemcentrx LLC Neuartige sez6-modulatoren und verfahren zur verwendung
SG11201601424PA (en) 2013-08-28 2016-03-30 Stemcentrx Inc Site-specific antibody conjugation methods and compositions
CA2939093A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
CA2949349A1 (en) 2014-05-26 2015-12-03 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding
US20170196954A1 (en) 2014-07-15 2017-07-13 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
EP3012269A1 (de) 2014-10-20 2016-04-27 Erhard Hofer Zytokin-ähnliches 1 (CYTL1)-Protein und Verwendungen davon
DK3244911T3 (da) 2015-01-12 2019-12-16 Rigshospitalet Copenhagen Univ Hospital Fremgangsmåde til bestemmelse af en sandsynlig virkning af en behandling til forbedring af mandlig ufrugtbarhed
WO2016127149A2 (en) 2015-02-06 2016-08-11 Cell Idx, Inc. Antigen-coupled immunoreagents
CA2981509A1 (en) 2015-03-30 2016-10-06 The Board Of Regents Of The Nevada System Of Higher Educ. On Behalf Of The University Of Nevada, La Compositions comprising talens and methods of treating hiv
JP6924151B2 (ja) 2015-05-29 2021-08-25 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 免疫寛容及び非免疫寛容エラスチン様組換えペプチドならびに使用方法
EP3303591B1 (de) 2015-06-01 2019-04-03 Medigene Immunotherapies GmbH T-zell-rezeptor-bibliothek
NZ737423A (en) 2015-06-01 2019-08-30 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
AU2016354000A1 (en) 2015-11-09 2018-05-17 Immune Design Corp. Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof
KR20180074699A (ko) 2015-11-09 2018-07-03 이뮨 디자인 코포레이션 이종 핵산을 발현하는 rna 레플리콘의 발현 및 투여를 위한 레트로바이러스 벡터
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP2018537976A (ja) 2015-11-25 2018-12-27 アカデミシュ・ジークンホイス・ライデン 組換えセリンプロテアーゼ
DK3394247T3 (da) 2015-12-23 2021-04-12 Medigene Immunotherapies Gmbh Ny generering af antigen-specifikke tcr'er
EP3443001A4 (de) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. Regulierte bioschaltkreissysteme
CN109415623B (zh) 2016-04-15 2022-07-08 拜克门寇尔特公司 光敏大分子及其用途
CN109641941B (zh) 2016-05-16 2023-06-16 哈佛大学校长及研究员协会 用于纯化和激活肉毒杆菌神经毒素的方法
WO2018026283A1 (en) 2016-08-04 2018-02-08 Stichting Vumc Embryonic angiogenesis markers and diagnostic and therapeutic strategies based thereon
WO2018148671A1 (en) 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Hla-based methods and compositions and uses thereof
MX2020001528A (es) 2017-08-14 2020-08-03 Univ Georgia Proteinas que tienen actividad de degradacion de la capsula neumococal y metodos de uso.
US11198722B2 (en) 2017-10-06 2021-12-14 University Of Utah Research Foundation Immune tolerant elastin-like peptide tetramer guided nanoparticles and methods of use
KR102490850B1 (ko) 2018-02-26 2023-01-26 메디진 이뮤노테라피스 게엠바하 Nyeso t 세포 수용체
EP3806888B1 (de) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie
WO2020030631A1 (en) 2018-08-06 2020-02-13 Medigene Immunotherapies Gmbh Ha-1 specific t cell receptors and their use
WO2020070089A1 (en) 2018-10-01 2020-04-09 Ospedale San Raffaele S.R.L. Chromogranin a and uses thereof
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
BR102019025989A2 (pt) 2018-12-14 2020-06-23 Beckman Coulter, Inc. Modificação de corantes poliméricos e aplicações
EP3899954A4 (de) 2018-12-21 2022-09-14 BioNTech US Inc. Verfahren und systeme zur vorhersage von hla-klasse-ii-spezifischen epitopen und charakterisierung von cd4+-t-zellen
BR112021017744A2 (pt) 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
EP3714941A1 (de) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4-tcrs
CN113840834A (zh) 2019-04-04 2021-12-24 基因医疗免疫疗法有限责任公司 Magea1特异性t细胞受体及其用途
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
EP3983538A1 (de) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2-zusammensetzungen und verfahren zur abstimmbaren regulierung
CA3146227A1 (en) 2019-07-09 2021-01-14 Medigene Immunotherapies Gmbh Magea10 specific t cell receptors and their use
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021067741A1 (en) 2019-10-02 2021-04-08 University Of Georgia Research Foundation, Inc. Glycopeptides for inducing an immune response and methods of use
WO2021102389A1 (en) 2019-11-22 2021-05-27 University Of Georgia Research Foundation, Inc. Tetanus toxoid and crm-based peptides and methods of use
US20230008380A1 (en) 2019-12-09 2023-01-12 University Of Georgia Research Foundation, Inc. M. tuberculosis ag85 proteins and methods of use
US20230285519A1 (en) 2020-07-17 2023-09-14 University Of Georgia Research Foundation, Inc. B-glucuronidase proteins having pneumococcal capsule degrading activity and methods of use
BR112023005296A2 (pt) 2020-09-24 2023-04-25 Medigene Immunotherapies Gmbh Receptores de células t específicos de mage-a3 e uso dos mesmos
JP2024509725A (ja) 2021-02-05 2024-03-05 ベックマン コールター， インコーポレイテッド ポリマー色素－抗体コンジュゲート間の非特異的相互作用を阻止する組成物および方法
KR20240005865A (ko) 2021-05-07 2024-01-12 메디진 이뮤노테라피스 게엠바하 Prame 특이적 t 세포 수용체 및 키메라 공동 자극 수용체의 조합
WO2023025779A1 (en) 2021-08-25 2023-03-02 Medigene Immunotherapies Gmbh Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors
WO2023056460A1 (en) 2021-09-30 2023-04-06 Beckman Coulter, Inc. Water-soluble tetrahydropyrene based fluorescent polymers
WO2024041761A1 (en) 2022-08-23 2024-02-29 Medigene Immunotherapies Gmbh Combination of ny-eso-1 specific t cell receptors and chimeric co-stimulatory receptors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468464A (en) * 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4563424A (en) * 1979-11-05 1986-01-07 Genentech, Inc. Method and means for somatostatin protein conjugate expression
JPS54145289A (en) * 1977-11-08 1979-11-13 Genentech Inc Improving method of microbiological polypeptide displaying method and means
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4571421A (en) * 1979-11-05 1986-02-18 Genentech, Inc. Mammalian gene for microbial expression
CA1200773A (en) * 1980-02-29 1986-02-18 William J. Rutter Expression linkers
US4532207A (en) * 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
US4503142A (en) * 1982-06-25 1985-03-05 Litton Bionetics, Inc. Open reading frame vectors
US4559302A (en) * 1982-11-01 1985-12-17 Eli Lilly And Company DNA for directing transcription and expression of structural genes

Also Published As

Publication number Publication date
ATE68014T1 (de) 1991-10-15
JPH074255B2 (ja) 1995-01-25
US4703004A (en) 1987-10-27
JPS60222429A (ja) 1985-11-07
EP0150126A2 (de) 1985-07-31
EP0150126A3 (en) 1987-06-03
EP0150126B1 (de) 1991-10-02

Similar Documents

Publication Publication Date Title
DE3584260D1 (de) Die synthese eines proteins mittels eines identifizierungspeptids.
Sanger Chemistry of insulin: determination of the structure of insulin opens the way to greater understanding of life processes
Sanger Chemistry of insulin
Aquila et al. Complete amino acid sequence of the ADP/ATP carrier from beef heart mitochondria
DK0531404T3 (da) Ubiquitin-specifik protease
IE883612L (en) Vectors and compounds for direct expression of activated human protein c
Grant et al. Amino acid sequence of a collagenolytic protease from the hepatopancreas of the fiddler crab, Uca pugilator
Watson et al. The amino acid sequence of chymopapain from Carica papaya
ATE73460T1 (de) Peptide aus alpha-aminoboronsaeuren.
NZ232742A (en) Yeast heterologous protein production method, vectors, dna constructs and proteins so produced and aprotinin (1-58) so produced
Geschwind et al. The Structure of the β-Melanocyte-stimulating Hormone
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
ES2114539T3 (es) Expresion de polipeptidos recombinados con purificacion mejorada.
ZA8860B (en) Pancreatic secretory trypsin inhibitor and variants thereof produced by a recombinant host,process,expression vector and recombinant host therefor and pharmaceutical use thereof
EP0195680A3 (de) Proteinsynthese mit einem Identifizierungspeptid
Graf et al. Cathepsin D generates γ-endorphin from β-endorphin
Proost et al. Chemical synthesis, purification and folding of the human monocyte chemotactic proteins MCP-2 and MCP-3 into biologically active chemokines
McClintock et al. Two distinct pathways of the streptokinase-mediated activation of highly purified human plasminogen
EP0528686B8 (de) Verfahren zur Herstellung von Peptiden
DE69735242D1 (de) N-terminal verlängerte proteine exprimiert in hefe
BR9714133A (pt) ácido nucleico isolado, molécula do mesmo, sonda, vetor de expressão recombinante, célula, polipeptìdeo, proteìna de fusão formulação de vacina e processos para produzir um polipeptìdeo de h. pylori, para detctar a presença de um ácido nucleico de helicobacter em uma amostra, para tratar ou reduzir um risco de infecção por h. pylori em um indivìduo e para produzir uma formulação de vacina
DE3686365D1 (de) Herstellungsverfahren fuer humanes atriales natriuretisches polypeptid.
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
KR860008282A (ko) 재조합 사람 레닌의 제조방법
Goodman et al. Pyrrolidonecarboxylic acid at the N-terminal positions of polypeptide chains from leopard shark immunoglobulins

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: EASTMAN KODAK CO., ROCHESTER, N.Y., US

8328 Change in the person/name/address of the agent

Free format text: BLICKLE, W., DIPL.-ING., PAT.-ASS., 70327 STUTTGART

8327 Change in the person/name/address of the patent owner

Owner name: SIGMA-ALDRICH CO., ST. LOUIS, MO., US

8328 Change in the person/name/address of the agent

Free format text: MAIWALD GMBH, 80335 MUENCHEN